Insmed (INSM) Reports Q4 Loss of $0.85/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
February 23, 2018 7:30 AM ESTOn track to file NDA before the end of March and anticipate a priority reviewExtended amikacin liposome inhalation suspension (ALIS) intellectual property protection to 2035 with issuance of ninth U.S. patentStrengthened cash position through the public offering of $450 million of convertible senior notes in January 2018 Completed the hiring of 71 therapeutic specialists and 5 key account directors to support disease state awareness efforts in the U.S.
BRIDGEWATER, N.J., Feb. 23, 2018 (GLOBE... More
